Technologies available for licensing, investment, joint ventures and R&D contracts in Ukraine, Azerbaijan, Georgia, Moldova, Uzbekistan

Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks

Google Translate

Patenting Information

Tag Cloud

Free counters!

Home Biotechnologies Pharmaceutical Compound for Treatment of Bone Tissue Diseases «Mebivid»

Pharmaceutical Compound for Treatment of Bone Tissue Diseases «Mebivid»


The efficiency of the developed compound «Mebivid» (complex of vitamin D3, calcium and bisphosphonate) is shown in the alimentary model of osteoporosis, which is based on the insufficient supply or metabolism deficiency of vitamin D3 and mineral components. In the process of osteoporosis the amounts of inorganic phosphate, general calcium and its fractions (albumin linked and ultrafiltrated) in organism decrease while the activity of alkaline phosphatase and its isoenzymes increase. Lipid metabolism and structure of bone tissue become disrupted as a result of the decrease of 25ОНD3 levels, which are used for determination of the amount of vitamin D3 in organism. Treatment of rats that have alimentary osteoporosis with «Mebivid» normalizes the above mentioned parameters and structurally-functional activity of bone tissue. These data indicate highly specific efficiency of the compound for treatment of osteoporosis.

Innovative Aspect and Main Advantages

The novelty of the developed compound lays in the effective combination of three components most essential for the treatment of bone system diseases: bisphosphonate, calcium, and vitamin D3 supplemented with vitamin Е. The form of bisphosphonate chosen (disodium salt dihydrate of methylenbisphosphonic acid) is more effective as compared to commercial preparations used for treatment of bone tissue pathologies due to its ability to prevent bone resorption by binding to the crystalline surface of hydroxyapatite and regulating osteoblasts activity. Calcium deficiency and chronic D-hypovitaminosis are involved in the development of osteoporosis in elderly people, women after the menopause and patients with oncologic diseases of bone tissue treated with corticosteroid hormones. Advantages of the compound are the usage of the most biologically acceptable form of vitamin D3 as protein complex with casein («Videin») and extension of storage duration.

Areas of Application

The compound belongs to the group of medical compounds which contain inorganic and organic ingredients, in particular calcium, vitamin D3, vitamin E and biologically accessible salt of methylenbisphosphonic acid. It can be used in pharmacology and medical practice for treatment of different forms of osteoporosis, osteomalacia and diseases, characterized by the softening of bone tissue.


Effect of complex preparation MEBIVID on structure-functional organization of the
bone tissue (B) and the proximal epiphyseal cartilage (A) of the tibia in rats under D-hypovitaminosis:
a – control; b – hypovitaminosis; c - + MEBIVID.

Stage of Development

A semi-industrial technology for the production of compound and its ready-to-use form «Pharmaceutical compound for treatment of bone tissue diseases – Mebivid» are developed and analytical normative documentation is prepared. Experimental batch of the compound is produced. The intellectual property rights are protected by the patent for invention № 85494 from 26.01.2009.

Contact Details

National Academy of Sciences of Ukraine Palladin Institute of Biochemistry, Transfer Technology Office
Contact person: Dr. Kozulina Olena Petrivna
Address: 9, Leontovicha str., 01601, Kyiv, Ukraine
Tel.: (+38 044) 235 7157
Fax: (+38 044) 279 6365
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it


0 #1 compound bows ebay 2014-10-20 13:13
I do not even know how I ended up here, but I thought this post was great.
I do not know who you are but certainly you are
going to a famous blogger if you are not already ;) Cheers!

Add comment

Security code

For additional technologies go to: